This Act directs the Department of Homeland Security (DHS) to assess how it currently uses Department of Energy (DOE) national laboratories for biodetection research and development and to align that work with DHS missions under the Homeland Security Act. It then requires a concrete strategy within 180 days that identifies biodetection technologies, establishes an acquisition plan to bring those technologies into existing BioWatch jurisdictions, and creates mechanisms for periodic external evaluations and cross-sector collaboration.
The strategy must be developed in coordination with federal, state, local, and tribal governments, higher education institutions, and the private sector, and it should define clear program and technical requirements. Finally, the Act requires a one-year update to Congress on implementation progress and any challenges, ensuring ongoing oversight and accountability for biodetection modernization.
At a Glance
What It Does
The Secretary of Homeland Security must assess DHS’s use of DOE national laboratories for biodetection R&D and deliver a strategy within 180 days that outlines technology identification, an acquisition plan for BioWatch jurisdictions, external evaluations, and cross-sector collaboration.
Who It Affects
DHS program offices, DOE national laboratories, BioWatch jurisdictions (federal, state, local, tribal), procurement offices, institutions of higher education, and private-sector vendors supplying biodetection tech.
Why It Matters
It creates a formal, cross-agency pathway to modernize biodetection capabilities, with external validation and a coordinated procurement approach to ensure BioWatch remains current and capable.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill begins by requiring DHS to assess how it currently partners with DOE national laboratories on biodetection research and development, tying this effort to authorities in the Homeland Security Act. It then requires a strategy, due within 180 days, that will identify biodetection technologies capable of meeting mission needs, outline how DHS will acquire and deploy those technologies across BioWatch jurisdictions, and specify how external evaluations will identify gaps and contingency plans.
The strategy must also define program and technical requirements and be developed in partnership with federal, state, local, and tribal governments, colleges and universities, and the private sector.
Additionally, the Act calls for ongoing collaboration with DOE labs and other partners to ensure the technologies are properly acquired, tested, and integrated into the biodetection network, with a focus on formal evaluation of performance and risk mitigation. Not later than one year after enactment, DHS must provide Congress with an update on the assessment and strategy, including challenges to implementation.
The bill frames a deliberate, governance-led approach to updating biodetection capabilities that will affect procurement practices, lab partnerships, and state and local biosurveillance efforts.
The Five Things You Need to Know
The bill requires DHS to assess current DOE lab use for biodetection R&D.
Within 180 days, DHS must submit a strategy identifying technologies, an acquisition plan for BioWatch, and external evaluations.
The strategy must partner with federal, state, local, and Tribal governments, higher education, and private sector entities.
Periodic external evaluations will identify gaps and contingency plans if technologies fail.
A one-year post-enactment update to Congress is required on progress and challenges.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This Act may be cited as the DHS Biodetection Improvement Act. The short title provides a formal, easily referenced label for the statute and sets the scope for the authorized biodetection modernization effort.
DHS assessment of DOE lab use for biodetection
The Secretary of Homeland Security shall assess how DHS has utilized DOE national laboratories and sites for biodetection research and development in carrying out DHS missions, referencing the Homeland Security Act of 2002 (6 U.S.C. 189). This establishes the baseline understanding of current collaborations and capabilities as a prerequisite to strategic planning.
Strategy for biodetection R&D and procurement
Not later than 180 days after enactment, the Secretary shall submit a strategy to Congress that (1) identifies biodetection technologies that can meet mission needs, informed by DHS capability analyses and studies such as the National Re-Assessment of the BioWatch Collector Network; (2) develops an acquisition plan to procure and provide these technologies to existing BioWatch jurisdictions in compliance with Federal law and DHS directives; (3) conducts periodic external evaluations to identify gaps and contingency plans if technologies underperform; and (4) supports partnerships with Federal, State, local, and Tribal governments, higher education institutions, and private sector entities to define program and technical requirements for future biodetection programs.
Reports to Congress
Not later than one year after enactment, DHS shall provide to the House Committee on Homeland Security and the Senate Committee on Homeland Security and Governmental Affairs an update of the assessment and strategy, including any challenges to implementation.
This bill is one of many.
Codify tracks hundreds of bills on Government across all five countries.
Explore Government in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- DHS program offices and BioWatch program managers, who gain a clearer, coordinated path for implementation and oversight.
- DOE national laboratories, which will participate in formalized collaboration and funding for biodetection R&D.
- BioWatch jurisdictions (federal, state, local, and Tribal) that will gain access to evaluated technologies and an integrated procurement pathway.
- Higher education institutions partnering on research and development and on programmatic requirements.
- Private-sector biodetection technology vendors that participate in the procurement ecosystem.
- Federal, State, Local, and Tribal public health and emergency management bodies benefiting from updated surveillance tools.
Who Bears the Cost
- DHS, including procurement and program management budgets, to implement and oversee the strategy.
- DOE national laboratories' related research costs and coordination activities.
- BioWatch jurisdictions incurring deployment and integration costs for new technologies.
- State and local governments may bear costs associated with implementing and training for new systems.
- Private vendors may incur bid/response costs and competition requirements to supply new technologies.
Key Issues
The Core Tension
The central dilemma is whether to prioritize rapid modernization of biodetection capabilities through accelerated interagency collaboration and procurement, or to prioritize thorough, external validation and governance steps that may slow deployment and increase upfront costs.
The bill creates a formal, cross-agency pathway for biodetection modernization that hinges on interagency collaboration, external validation, and a clear procurement framework. While this can improve accountability and capabilities, it also raises questions about cost growth, timing, and the transfer of responsibility across agencies.
Tensions may arise between accelerating access to newer technologies and satisfying rigorous procurement, evaluation, and interoperability standards. The plan relies on cooperation among federal, state, local, and Tribal actors, academia, and the private sector, which requires robust coordination and funding to realize the intended improvements.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.